CASP9 Antibodies

Target Information

Involved in the activation cascade of caspases responsible for apoptosis execution. Binding of caspase-9 to Apaf-1 leads to activation of the protease which then cleaves and activates caspase-3. Promotes DNA damage-induced apoptosis in a ABL1/c-Abl-dependent manner. Proteolytically cleaves poly(ADP-ribose) polymerase (PARP). Isoform 2 lacks activity is an dominant-negative inhibitor of caspase-9. Belongs to the peptidase C14A family. Ubiquitous, with highest expression in the heart, moderate expression in liver, skeletal muscle, and pancreas. Low levels in all other tissues. Within the heart, specifically expressed in myocytes. 4 alternatively spliced human isoforms have been reported. Note: This description may include information from UniProtKB.

Alternate Names

25 kDa caspase-9 dominant negative protein; AI115399; APAF-3; APAF3; Apaf3; apoptotic protease activating factor 3; Apoptotic protease Mch-6; apoptotic protease Mch-6; Apoptotic protease-activating factor 3; AW493809; Casp; CASP-9; Casp-9-CTD; CASP9; Casp9; Casp9_v1; caspase 9; caspase 9, apoptosis-related cysteine peptidase; caspase 9, apoptosis-related cysteine protease; Caspase 9, isoform CRA_a; Caspase-9; caspase-9 dominant negative form; Caspase-9 long isoform; Caspase-9 subunit p10; Caspase-9 subunit p35; caspase-9-carboxyl-terminal divergent; CASPASE-9c; Caspase9; ICE-; ICE-LAP6; Ice-Lap6; ICE-like apoptotic protease 6; Ice-like apoptotic protease 6; MCH6; Mch6; OTTMUSP00000010525; PPP1R56; protein phosphatase 1, regulatory subunit 56; RNCASP9